Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial

Diabetes Care

Volumn 26, Issue 3, 2003, Pages 784-790

  Hollander, Priscilla A ^a   Levy, Philip ^b   Fineman, Mark S ^c   Maggs, David G ^c   Shen, Larry Z ^c   Strobel, Susan A ^c   Weyer, Christian ^c   Kolterman, Orville G ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Phoenix Endocrinology Clinic   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAMLINTIDE; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGED; AMYLOID; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0042167233     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.3.784     Document Type: Article

References (35)

1. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998
2. UK Prospective Diabetes Study Group: Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258, 1995
3. Klein R, Klein BE, Moss SE, Cruickshanks KJ: The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care 19:744-750, 1996
4. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS: Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care 16:21-31, 1993
5. Riddle MC: Should obese type 2 diabetic patients be treated with insulin? In Difficult Diabetes. Gill GV, Pickup JC, Williams G, Eds. Oxford, Blackwell Science, 2001, p. 94-112
6. Purnell JQ, Weyer C: Weight effect of current and experimental diabetes drugs: from promotion to alleviation of obesity. Treatments Endocrinol 21:23-37, 2003
7. American Diabetes Association: Postprandial blood glucose (Consensus Statement). Diabetes Care 24:775-778, 2001
8. Lebovitz HE: Postprandial hyperglycaemic state: importance and consequences (Review Article). Diabetes Res Clin Pract 40 (Suppl.):S27-S28, 1998
9. Gurlek A, Erbas T, Gedik O: Frequency of severe hypoglycaemia in type 1 and type 2 diabetes during conventional insulin therapy. Exp Clin Endocrinol Diabetes 107:220-224, 1999
10. Jaap AJ, Jones GC, McCrimmon RJ, Deary IJ, Frier BM: Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin. Diabet Med 15:398-401, 1998
11. Hepburn DA, MacLeod KM, Pell AC, Scougal IJ, Frier BM: Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 10:231-237, 1993
12. Koda JE, Fineman MS, Kolterman OG, Caro JF: 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls (Abstract). Diabetes 44 (Suppl. 1):238A, 1995
13. Weyer C, Maggs DG, Young AA, Kolterman OG: Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and/type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 7:1353-1373, 2001
14. Edelman SV, Weyer C: Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol Ther 4:175-189, 2002
15. Buse JB, Weyer C, Maggs DG: Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 20:137-144, 2002
16. Fineman MS, Giotta MP, Thompson RG, Kolterman OG, Koda JE: Amylin response following Sustacal® ingestion is diminished in type II diabetic patients treated with insulin (Abstract). Diabetologia 39 (Suppl. 1):A149, 1996
17. Young A, Moore C, Herich J, Beaumont K: Neuroendocrine actions of amylin. In The CGRP Family: Calcitonin Gene-Related Peptide (CGRP), Amylin, and Adrenomedullin. Poyner D, Marshall I, Brain SD, Eds. Georgetown, Texas, Landes Bioscience, 2000, p. 91-102
18. Gedulin BR, Rink TJ, Young AA: Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46:67-70, 1997
19. Young AA, Gedulin B, Vine W, Percy A, Rink TJ: Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38:642-648, 1995
20. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman O: The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 34:504-508, 2002
21. Vella A, Lee JS, Camilleri M, Szarka LA, Burton DD, Zinsmeister AR, Rizza RA, Klein PD: Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and type 2 diabetes mellitus. Neurogastroenterol Motil 14:123-131, 2002
22. Maggs DG, Weyer C, Crean J, Wang Y, Burrell T, Finemam M, Kornstein J, Schwartz S, Guiterrez M, Kolterman O: Mealtime amylin replacement with pramlintide markedly improves postprandial glucose excursions when added to insulin lispro in patients with type 2 diabetes: a dose-timing study (Abstract). Diabetologia (Suppl. 2) 45:A264, 2002
23. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG: Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin and C-peptide concentrations in patients with type II diabetes. Diabet Med 14:547-555, 1997
24. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 25 (Suppl. 1):S33-S49, 2002
25. DCCT Research Group: Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 90:450-459, 1991
26. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG: Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther 4:51-61, 2002
27. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL: Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103:491-497, 1997
28. Aviles-Santa L, Sinding J, Raskin P: Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 131:182-188, 1999
29. Morley JE, Flood JF: Amylin decreases food intake in mice. Peptides 12:865-869, 1991
30. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, D'Alessio DA, Air EL, Woods SC: Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 142:5035-5038, 2001
31. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SC, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J: Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 21:1288-1294, 1998
32. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J: Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2:105-112, 2000
33. Gottlieb A, Velte M, Fineman M, Kolterman O: Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks (Abstract). Diabetes 49 (Suppl. 1):A109, 2000
34. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG: A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25:724-730, 2002
35. Riddle MC: Pramlintide: an agent for glycemic control plus weight control. Diabetes Technol Ther 4:63-65, 2002